Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 19/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.68 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.68 |
| ▸ | CYP11A1 | P05108 | 1/20 | 0.68 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.68 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.68 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.68 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.68 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rogletimide SCHEMBL9372682 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP3A4CYP17A1CYP11A1TBXAS1 | |
| Rogletimide SCHEMBL28110686 | 0.97 | CYP19A1 (0.94) | CYP19A1CYP3A4CYP17A1CYP11A1TBXAS1 | |
| SCHEMBL3296751 | 0.85 | CYP19A1 (1.00) | CYP19A1 | |
| Glutethimide SCHEMBL113708 | 0.84 | CYP19A1 (0.72) | CYP19A1CYP3A4CYP17A1CYP11A1TBXAS1 | |
| Glutethimide SCHEMBL21119240 | 0.84 | CYP19A1 (0.72) | CYP19A1CYP3A4CYP17A1CYP11A1TBXAS1 | |
| Glutethimide SCHEMBL113709 | 0.84 | CYP19A1 (0.72) | CYP19A1CYP3A4CYP17A1CYP11A1TBXAS1 | |
| SCHEMBL9531145 | 0.83 | CYP19A1 (1.00) | CYP19A1 | |
| SCHEMBL16509358 | 0.83 | CYP19A1 (0.75) | CYP19A1CYP3A4CYP17A1CYP11A1TBXAS1 | |
| Aminoglutethimide SCHEMBL116988 | 0.81 | CYP19A1 (1.00) | CYP19A1CYP3A4CYP17A1CYP11A1TBXAS1 | |
| Aminoglutethimide SCHEMBL1230613 | 0.81 | CYP19A1 (1.00) | CYP19A1CYP3A4CYP17A1CYP11A1TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 11417 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116861-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-04-30 | — | — | US | claimed |
| US-12522572-B2 | Isoxazole hydroxamic acids as histone deacetylase 6 inhibitors | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2026-01-13 | — | — | US | claimed |
| EP-4524131-A1 | SMALL MOLECULES FOR TREATING CANCER, INHABITING CHEMOKINE ACTIVITY AND/OR INDUCING CELL DEATH | AlonBio Ltd. (IL) | 2025-03-19 | — | — | EP | claimed |
| US-12202803-B2 | Small molecules for treating cancer, inhibiting chemokine activity and/or inducing cell death | ALONBIO LTD. (IL) | 2025-01-21 | — | — | US | claimed |
| US-20240343697-A1 | ISOXAZOLE HYDROXAMIC ACIDS AS HISTONE DEACETYLASE 6 INHIBITORS | THE GEORGE WASHINGTON UNIVERSITY, A CONGRESSIONALLY CHARTERED NOT-FOR-PROFIT CORPORATION (US) | 2024-10-17 | — | — | US | claimed |
| US-12109219-B2 | Cannabinoid receptor modulators | ARENA PHARMACEUTICALS, INC. (US) | 2024-10-08 | — | — | US | claimed |
| WO-2024026505-A2 | DISRUPTION OF TELOCYTE ACTIVITY | PATEL AMIT (US) | 2024-02-01 | — | — | WO | claimed |
| US-20240002347-A1 | SMALL MOLECULES FOR TREATING CANCER, INHIBITING CHEMOKINE ACTIVITY AND/OR INDUCING CELL DEATH | ALONBIO LTD. (IL) | 2024-01-04 | — | — | US | claimed |
| US-20220401541-A1 | INTRATUMORAL ADMINISTRATION OF IMMUNE CELLULAR THERAPEUTICS | FIBROBIOLOGICS, INC. | 2022-12-22 | — | — | US | claimed |
| EP-3441089-B1 | TREATMENT METHODS USING ADENOVIRUS | VASCULAR BIOGENICS LTD (IL) | 2022-12-14 | — | — | EP | claimed |
| EP-1019034-A2 | ANTIOXIDANT ENHANCEMENT OF THERAPY FOR HYPERPROLIFERATIVE CONDITIONS | Atherogenics, Inc. (US) | 2000-07-19 | — | — | EP | claimed |
| US-6020327-A | Control of hair growth | THE CENTRAL SHEFFIELD UNIVERSITY HOSPITALS NHS TRUST (GB) | 2000-02-01 | — | — | US | claimed |
| WO-1999001118-A9 | ANTIOXIDANT ENHANCEMENT OF THERAPY FOR HYPERPROLIFERATIVE CONDITIONS | ATHEROGENICS INC (US) | 1999-05-20 | — | — | WO | claimed |
| WO-1999001118-A2 | ANTIOXIDANT ENHANCEMENT OF THERAPY FOR HYPERPROLIFERATIVE CONDITIONS | ATHEROGENICS, INC. (US) | 1999-01-14 | — | — | WO | claimed |
| EP-0516278-A1 | Use of anti-mullerian hormone for reversal of female sexual phenotype in poultry | MERCK & CO. INC. (US) | 1992-12-02 | — | — | EP | claimed |
| EP-0514015-A1 | Control of sex differentiation in fish | MERCK & CO. INC. (US) | 1992-11-19 | — | — | EP | claimed |
| US-5162337-A | Administering Steroid Biosynthesis Inhibitors | MERCK & CO., INC. (US) | 1992-11-10 | — | — | US | claimed |
| WO-1992018132-A1 | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA COMTAINING A 5 ALPHA-REDUCTASE INHIBITOR | MERCK & CO., INC. (US) | 1992-10-29 | — | — | WO | claimed |
| EP-0479570-A2 | Animal growth promotion with aromatase inhibitors | MERCK & CO. INC. (US) | 1992-04-08 | — | — | EP | claimed |
| EP-0433084-A2 | Use of aromatese inhibitors for the reversal of female sexual phenotype in poultry | MERCK & CO. INC. (US) | 1991-06-19 | — | — | EP | claimed |